These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 18624618)

  • 1. Microbial safety of cell based medicinal products--what can we learn from cellular blood components?
    Montag T; Nicol SB; Schurig U; Heiden M; Huber H; Sanzenbacher R; Flory E; Schwanig M; Schneider CK
    Clin Chem Lab Med; 2008; 46(7):963-5. PubMed ID: 18624618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Problems in microbial safety of advanced therapy medicinal products. Squaring the circle].
    Montag-Lessing T; Störmer M; Schurig U; Brachert J; Bubenzer M; Sicker U; Beshir R; Spreitzer I; Löschner B; Bache C; Becker B; Schneider CK
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):45-51. PubMed ID: 20012926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacterial contamination of platelet concentrates prepared by different methods: results of standardized sterility testing in Germany.
    Walther-Wenke G; Doerner R; Montag T; Greiss O; Hornei B; Knels R; Strobel J; Volkers P; Däubener W;
    Vox Sang; 2006 Apr; 90(3):177-82. PubMed ID: 16507017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of bacterial contamination in apheresis platelet products: American Red Cross experience, 2004.
    Fang CT; Chambers LA; Kennedy J; Strupp A; Fucci MC; Janas JA; Tang Y; Hapip CA; Lawrence TB; Dodd RY;
    Transfusion; 2005 Dec; 45(12):1845-52. PubMed ID: 16371037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacterial safety of cell-based therapeutic preparations, focusing on haematopoietic progenitor cells.
    Störmer M; Wood EM; Schurig U; Karo O; Spreitzer I; McDonald CP; Montag T
    Vox Sang; 2014 May; 106(4):285-96. PubMed ID: 24697216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sterility testing of cell therapy products: parallel comparison of automated methods with a CFR-compliant method.
    Khuu HM; Patel N; Carter CS; Murray PR; Read EJ
    Transfusion; 2006 Dec; 46(12):2071-82. PubMed ID: 17176318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Current concept for the microbiological safety of cell-based medicinal products].
    Schurig U; Karo JO; Sicker U; Spindler-Raffel E; Häckel L; Spreitzer I; Bekeredjian-Ding I
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1225-32. PubMed ID: 26369764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring bacterial contamination of blood components in Germany: effect of contamination reduction measures.
    Walther-Wenke G; Wirsing von König CH; Däubener W; Heiden M; Hoch J; Hornei B; Volkers P;
    Vox Sang; 2011 May; 100(4):359-66. PubMed ID: 21029110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacterial detection of platelets: current problems and possible resolutions.
    Blajchman MA; Beckers EA; Dickmeiss E; Lin L; Moore G; Muylle L
    Transfus Med Rev; 2005 Oct; 19(4):259-72. PubMed ID: 16214015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Viral safety of biological medicinal products].
    Stühler A; Blümel J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1198-202. PubMed ID: 25123140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacteria in blood for transfusion. A review.
    Sazama K
    Arch Pathol Lab Med; 1994 Apr; 118(4):350-65. PubMed ID: 8166585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Microorganisms in drugs and cosmetics - occurrence, harms and consequences in hygienic manufacturing (author's transl)].
    Grigo J
    Zentralbl Bakteriol Orig B; 1976 Jul; 162(3-4):233-87. PubMed ID: 983538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reducing the risk of bacterial contamination of cellular blood components.
    Blajchman MA
    Dev Biol (Basel); 2000; 102():183-93. PubMed ID: 10794105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of bacterial contamination in blood and blood products at the National Blood Service Zimbabwe.
    Makuni N; Simango C; Mavenyengwa RT
    J Infect Dev Ctries; 2015 Apr; 9(4):421-4. PubMed ID: 25881533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basics of flow cytometry-based sterility testing of platelet concentrates.
    Mohr H; Lambrecht B; Bayer A; Spengler HP; Nicol SB; Montag T; Müller TH
    Transfusion; 2006 Jan; 46(1):41-9. PubMed ID: 16398729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges for Cell-Based Medicinal Products From a Pharmaceutical Product Perspective.
    Jere D; Sediq AS; Huwyler J; Vollrath I; Kardorff M; Mahler HC
    J Pharm Sci; 2021 May; 110(5):1900-1908. PubMed ID: 33307042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raising the standard: changes to the Australian Code of Good Manufacturing Practice (cGMP) for human blood and blood components, human tissues and human cellular therapy products.
    Wright C; Velickovic Z; Brown R; Larsen S; Macpherson JL; Gibson J; Rasko JE
    Pathology; 2014 Apr; 46(3):177-83. PubMed ID: 24614714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies of bacteria screening in cellular blood components.
    Montag T
    Clin Chem Lab Med; 2008; 46(7):926-32. PubMed ID: 18624615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacterial contamination in blood components and preventative strategies: an overview.
    Vasconcelos E; Seghatchian J
    Transfus Apher Sci; 2004 Oct; 31(2):155-63. PubMed ID: 15501419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Absolute" sterility and "absolute" freedom from particle contamination.
    Knapp JZ
    PDA J Pharm Sci Technol; 1998; 52(4):173-81. PubMed ID: 9752713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.